OpenAlex
PricingAboutJobs
Log inGet started
Work

Efficacy of BIBF 1120 in patients with IPF is dose-dependent: Results from the TOMORROW trial

HTML

Year: 2011
Type: article
Source: European Respiratory Journal
Authors: Ulrich Costabel, Luca Richeldi, Moisés Selman, Dong Soon Kim, Kevin K. Brown, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel, Roland M. du Bois
Institutions: Ruhrlandklinik, University of Duisburg-Essen, University of Modena and Reggio Emilia, Instituto Nacional de Enfermedades Respiratorias, Asan Medical Center, National Jewish Health, University of Michigan, Michigan Medicine, Duke University, Duke Medical Center, University of Washington, Boehringer Ingelheim (France), Boehringer Ingelheim (Germany), Imperial College London
Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, dose-dependent efficacy, forced vital capacity decline, acute exacerbation, oxygen saturation, gastrointestinal adverse effects, drug safety, lung fibrosis progression, antifibrotic therapy, treatment discontinuation
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W1775621272
FWCI:
Cites:
Cited by:
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security